Locations:
Search
Cardiovascular drug affects cancer cell protein pathways
Study examines concordance between commercially available genomic tests
Cleveland Clinic researchers first to show sensitivity of IDH1/2 mutations to PARP inhibitor olaparib
Disease-related, clinical and discharge-associated factors
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Multicenter study shows survival benefit for patients ≤ 65
JAK inhibitors, the hedgehog pathway and answers for anemia
Prevention, early detection best strategy
Researchers add genomic data to their model
Prospective study needed to determine best margins
Helps reduce risk of premature menopause
Advertisement
Advertisement